Immuno-oncology firm Agenus (Nasdaq:AGEN) and its partner GSK (NYSE:GSK) have announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 Phase 3 trial of an experimental respiratory syncytial virus (RSV) vaccine.
RSV infects most children before the age of 2. Some 75,000 to 125,000 children are hospitalized as a result of the virus annually, according to data from the National Institute of Allergy and Infectious Diseases.
But RSV can also pose a risk to older adults, especially those with chronic conditions, as the CDC noted.
The Agenus and GSK study focused on adults at least 60 years of age.
The analysis of the Phase 3 trial was the first to show a statistically significant and clinically meaningful efficacy in older adults.
Agenus and GSK note that the AReSVi 006 study exceeded its primary endpoint without observing any unexpected safety concerns.
The companies hope to file regulatory sub…